Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788693 | 0.74 | NOTUM (0.47) | HPGDTSHRALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1642678 | 0.72 | DAO (0.39) | HPGDTSHRALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4919212 | 0.70 | L3MBTL1 (0.41) | TSHRBCHEALDH1A1KDM4EHSD17B10 | |
| SCHEMBL9587424 | 0.70 | BCHE (0.37) | HPGDBCHEALDH1A1KDM4EHSD17B10 | |
| SCHEMBL20138330 | 0.68 | RAB9A (0.50) | HPGDTSHRALDH1A1SIGMAR1KMT2A | |
| SCHEMBL289936 | 0.67 | NR1H2 (0.42) | BCHEL3MBTL1 | |
| SCHEMBL6141961 | 0.66 | DRD2 (0.60) | HPGDTSHRHSP90AA1HRH4ALDH1A1 | |
| SCHEMBL427310 | 0.65 | MGLL (0.71) | — | |
| SCHEMBL5470285 | 0.65 | GAA (0.60) | BCHEALDH1A1KMT2ALMNARAB9A | |
| SCHEMBL201716 | 0.65 | POLB (0.43) | TSHRBCHEALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | HPGD 4601/4885TSHR 2505/4885BCHE 3244/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | HPGD 4601/4885TSHR 2505/4885BCHE 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.